Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre

British Journal of Dermatology

Volumn 167, Issue 2, 2012, Pages 411-416

  Wee, J S ^a   Petrof, G ^a   Jackson, K ^a   Barker, J N W N ^a   Smith, C H ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CHLORPHENIRAMINE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; HYDROCORTISONE; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; CHEST TIGHTNESS; FEMALE; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; UNITED KINGDOM;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84864416925     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10931.x     Document Type: Article

References (20)

1. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
2. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multi-centre, double-blind trial. Lancet 2005; 36: 1367-74.
3. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31e1-15.
4. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
5. Lecluse LL, Piskin G, Mekkes JR, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008; 159: 527-36.
6. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
7. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
8. Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-61.
9. Kleyn CE, Griffiths CE,. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther 2006; 6: 797-805.
10. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
11. Moss AC, Fernandez-Becker N, Jo Kim K, et al. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008; 28: 221-7.
12. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term effect of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
13. Merck Sharp, and, Dohme (MSD),. Remicade. Summary of Product Characteristics. Hoddesdon, U.K.: MSD, 2002.
14. Buch MH, Bryer D, Lindsay S, et al. Shortening infusion times for infliximab administration. Rheumatology 2008; 45: 485-6.
15. Clare DF, Alexander FC, Mike S, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009; 21: 71-5.
16. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
17. Kapetanovic MC, Larsson L, Truedsson L, et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006; 8: R131.
18. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
19. Merck Sharp, Dohme and (MSD),. Remicade. Summary of Product Characteristics. Hoddesdon, U.K.: MSD, 2011.
20. Bhat S, Sharma D, Doherty P, et al. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis 2010; 16: 1922-5.